Of note, downregulation of the well-established histological marker of SS, the prosurvival BCL2 protein30–32, was also observed following TAK-981 treatment, without changes in other BCL2 family member proteins (Fig. 1H and Supplementary Fig. 2C). The gene discussed is BCL2; the disease is synovial sarcoma.